|
⚲
|
| Mark Kessel | |
|---|---|
| Firm | |
| Address | 875 Third Avenue Third Floor New York, NY 10022 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM ($M) |
|---|---|---|---|---|---|
| Primrose Therapeutics Inc | 021-146420 | Executive Officer | 0.8 M of 1.5 M |
||
| Renavance Pharma Inc | 021-146063 | Director | 0.1 M of 0.1 M |
||
| Dynavax Technologies Corp | 021-142544 | Director | 0.2 M of 0.2 M |
||
| Oxigene Inc | 021-90825-9N | Director | 7.5 M of 7.5 M |
||
| Dynavax Technologies Corp | 021-42805 | Director | 20.1 M of 38.9 M |
||
| Renavance Pharma Inc | 021-132779 | Director | 0.5 M of 0.5 M |
||